Watch it now!

The FDA’s recent approval of EvolutTM TAVR for low-risk patients expands the use to potentially younger, more active patients signaling a significant shift in future treatment of symptomatic severe aortic stenosis. Learn from four leading cardiologists on the movement of TAVR into this low-risk patient population, how hospitals are increasing awareness among physicians and patients and the importance of connecting patients with heart teams. They also dive into parameters around hemodynamics and durability, excellence in patient outcomes, and how clinical practice and economics are evolving to meet this new demand. 


What You'll Learn

  • Why low-risk TAVR is changing the way severe symptomatic aortic stenosis patients are treated
  • Why heart teams offer the best treatment options for aortic stenosis patients
  • Which patients benefit most from TAVR vs. SAVR 
  • How the expansion of TAVR may impact hospital economics
  • How physicians are discussing options and clinical considerations with patients
  • Why cardiologists need to get the word out to referrers on which patients may benefit the most from TAVR 

Target Audience

  • Chiefs/Directors of Cardiology, Cardiologists, Interventional Cardiologists, Cardiac Surgeons
  • Cardiovascular Service Line Directors
  • Structural Heart Teams
  • TAVR Coordinators
  • Cardiology Administrators
  • Hospital C-Suite - COOs, CEOs, CFOs

Expert Panel


Steven Yakubov, MD

Director of the MidWest Cardiology Research Foundation,

Kendra J. Grubb, MD

Surgical Director, Structural Heart & Valve Center,
Emory University

Toby Rogers, MD, PhD

Interventional Cardiologist & Scientific Lead for Structural Heart Disease,
MedStar Washington Hospital Center

Mark J. Ricciardi, MD

Interventional Cardiologist,

Note: Medtronic’s Evolut TAVR platform is now indicated in the United States for symptomatic severe aortic stenosis patients across all surgical risk categories: extreme, high, intermediate and low.